ReviewJournal of clinical medicine2021
Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Association ofFrontiers in medicine · 2025Pooled it
- Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy forNutrients · 2022Pooled it
- Cardiovascular Diseases: Exploring Epidemiology, Pathophysiology, Risk Factors, and Medicinal Plant-Based Therapies: A Narrative Review.Health science reports · 2026Article
- Relationship BetweenCardiology research and practice · 2026Article
- Syndemics of Antimicrobial Resistance: Non-communicable Diseases, Social Deprivation, and the Rise of Multidrug-Resistant Infections.Infectious diseases and therapy · 2025Article
- Exploring the potential link between human papillomavirus infection and coronary artery disease: a review of shared pathways and mechanisms.Molecular and cellular biochemistry · 2025Review
- The Application of Mesoporous Silica Nanoparticles in Enhancing the Efficacy of Anti-Atherosclerosis Therapies: A Review.International journal of nanomedicine · 2025Review
- Review
- Association of prior tuberculosis with cardiovascular status in perinatally HIV-1-infected adolescents.Open heart · 2024Article
- The Detection ofPathogens (Basel, Switzerland) · 2024Article
- Time-dependent cardiovascular risks following pneumonia in inpatient and outpatient settings: A register-based cohort study.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Exposome in ischaemic heart disease: beyond traditional risk factors.European heart journal · 2024Review
- Impact ofFrontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- Article
- The FCGR2A Is Associated with the Presence of Atherosclerotic Plaques in the Carotid Arteries-A Case-Control Study.Journal of clinical medicine · 2023Article
- Atherosclerosis, Cardiovascular Disorders and COVID-19: Comorbid Pathogenesis.Diagnostics (Basel, Switzerland) · 2023Review
- Serum C reactive protein and procalcitonin are valuable predictors of coronary heart disease and poor prognosis in the elderly.American journal of translational research · 2023Article
- The Role of CMV Infection in Primary Lesions, Development and Clinical Expression of Atherosclerosis.Journal of clinical medicine · 2022Review
- Increased Risk to Develop Hypertension and Carotid Plaques in Patients with Long-LastingJournal of clinical medicine · 2022Article
- Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular diseases (ASCVD) are the major cause of mortality worldwide. Despite the continuous progress in ASCVD therapy, the residual risk persists beyond the management of traditional risk factors. Several infections including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.